PharmEasy Commits to Expanding Access to GLP-1 Therapies and Holistic Weight Management Support
Mr Gaurav Verma, Chief Business Officer at PharmEasy
“The rising burden of obesity and its associated health risks is deeply concerning. With the advent of GLP-1 medicines, managing weight and related conditions such as type 2 diabetes and fatty liver disease has become significantly more effective. At PharmEasy, we are committed to improving the affordability and accessibility of GLP-1 therapies for our consumers. At the same time, we recognize that medication alone may not be enough. Sustainable outcomes depend on the right nutrition, physical activity, and continuous medical supervision. That is why we are also building a comprehensive weight loss program with senior doctors, designed to support patients holistically in their weight management journey.”